Who owns retatrutide?
Eli Lilly funded the first large published obesity trial of retatrutide, which says so in its funding line.
GLP-1 / GIP / glucagon triple agonistUpdated
Short answer
Eli Lilly funded the first large published obesity trial of retatrutide, which says so in its funding line.[1]
The earlier diabetes dose-escalation trial also lists Eli Lilly and Company as its funder.[2]
What the registry and commentary show
The registry entry for the TRIUMPH-1 obesity trial names Eli Lilly and Company as its organisation.[3]
More questions on Retatrutide
More on Retatrutide
Sources
- 1Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 2LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 3A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.